SGLT2 Inhibitors for Stroke Reperfusion Edema Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic stroke fail to effectively decouple brain swelling from infarct volume, limiting the clinical management of secondary injury and neurological deterioration, and there is a lack of molecularly informed therapies that can reduce brain swelling independently of infarct size.
Innovation Solution
Administering sodium-glucose cotransporter 2 (SGLT2) inhibitors, particularly gliflozins like canagliflozin, to treat reperfusion edema in stroke patients, which are localized in astrocyte endfeet and reduce brain swelling independently of infarct volume.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional stroke treatments (rtPA, mechanical thrombectomy) are used to recanalize large cerebral arteries, then blood flow is restored and infarct volume is reduced, but brain swelling and secondary injury persist, limiting neurological recovery
Solution Approach 1:
The patent introduces SGLT2 inhibitors as an intermediary substance that mediates between restored blood flow and brain swelling. These inhibitors act on the sodium-glucose cotransporter 2 in astrocyte endfeet to block sodium influx, thereby preventing osmotic swelling while allowing the benefits of recanalization to manifest. This intermediary approach decouples the harmful effect of swelling from the beneficial restoration of blood flow.
Solution Approach 2:
The patent changes the physiological parameter of sodium transport by blocking SGLT2 activity. This parameter change (inhibiting sodium-glucose cotransport) directly affects the osmotic balance in astrocyte endfeet, preventing water influx and brain swelling. By modifying this specific transport parameter, the treatment addresses the harmful swelling effect without compromising the beneficial blood flow restoration achieved through recanalization.
2Object-affected harmful factors
If decompressive craniectomy is performed to treat severe brain swelling, then brain swelling is reduced and mortality is decreased, but the procedure is morbid and involves removing a large part of the cranium
Solution Approach 1:
The patent replaces the mechanical surgical intervention (decompressive craniectomy) with a pharmacological mechanism. Instead of mechanically removing bone to reduce swelling, the SGLT2 inhibitor blocks the molecular mechanism of swelling (sodium-glucose cotransport in astrocyte endfeet). This substitution eliminates the need for complex skull removal surgery while achieving the same goal of reducing brain swelling through a non-invasive chemical block.
Solution Approach 2:
The SGLT2 inhibitor serves as a molecular intermediary that blocks the pathophysiological mechanism of swelling without requiring mechanical intervention. By targeting the sodium-glucose cotransporter in astrocyte endfeet, the drug provides a non-surgical means to prevent water influx and reduce brain swelling, thereby avoiding the morbidity associated with craniectomy.
3Object-affected harmful factors
If treatments are used to reduce brain swelling, then swelling is decreased, but most treatments only reduce swelling in proportion to the reduction in infarct volume, failing to dissociate swelling from infarct size
Solution Approach 1:
The patent segments the pathophysiological processes into two independent components: infarct volume (tissue death) and brain swelling (osmotic edema). By targeting SGLT2 specifically in astrocyte endfeet, the treatment addresses swelling as a separate, modifiable parameter that can be reduced independently of infarct size. This segmentation allows swelling reduction to occur without requiring proportional reduction in infarct volume, as the drug acts on the swelling mechanism rather than the infarcted tissue.
Solution Approach 2:
The patent applies local quality by targeting SGLT2 specifically in astrocyte endfeet, which are located at the blood-brain barrier interface. This localized targeting allows the treatment to affect swelling mechanisms in the perivascular regions without affecting the infarcted parenchymal tissue. The localized action on astrocyte endfeet enables independent control of swelling from infarct size, as the drug modifies the osmotic properties of the extracellular space rather than directly treating the necrotic tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SGLT2 inhibitors like canagliflozin effectively reduce reperfusion edema and brain swelling, improving neurological function without affecting infarct size, thereby expanding the time window for thrombectomy and enhancing clinical outcomes.
Implementation Method 1
brain swelling is linked to the aberrant or maladaptive function of sodium transporters at the blood-brain barrier (BBB)... those belonging to the family of sodium-glucose co-transporters (SGLT)... SGLT2 inhibitors... reduce brain swelling
Implementation Method 2
the degree of brain swelling depends on infarct size... treatments that reduce swelling or edema do so only in proportion to the reduction in infarct volume... sodium transporters at the blood-brain barrier
Data Source
AI summary
The present invention provides methods for treating reperfusion edema in patients who have suffered a stroke, the methods comprising administering an effective amount of one or more inhibitors of sodium D-glucose cotransporter 2 (SGLT2). The invention further contemplates administration of SGLT2 inhibitors in combination with recombinant tissue plasminogen activator (rt-PA). Exemplary SGLT2 inhibitors include canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, re-mogliflozin etabonate, sergliflozin etabonate, sotagliflozin, tofogliflozin and combinations thereof.